These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Design of Multifaceted Antioxidants: Shifting towards Anti-Inflammatory and Antihyperlipidemic Activity. Tzara A; Lambrinidis G; Kourounakis A Molecules; 2021 Aug; 26(16):. PubMed ID: 34443516 [TBL] [Abstract][Full Text] [Related]
4. Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. Alaarg A; Zheng KH; van der Valk FM; da Silva AE; Versloot M; van Ufford LC; Schulte DM; Storm G; Metselaar JM; Stroes ES; Hamers AA Vascul Pharmacol; 2016 Jul; 82():51-9. PubMed ID: 27189780 [TBL] [Abstract][Full Text] [Related]
5. I Ma L; Qian L; Ying Q; Zhang Y; Zhou C; Wu G Mol Cell Endocrinol; 2017 Jan; 440():80-92. PubMed ID: 27725191 [TBL] [Abstract][Full Text] [Related]
6. Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides. Petraki MP; Mantani PT; Tselepis AD Curr Pharm Des; 2009; 15(27):3146-66. PubMed ID: 19754388 [TBL] [Abstract][Full Text] [Related]
7. Effects of niacin on atherosclerosis and vascular function. Ruparelia N; Digby JE; Choudhury RP Curr Opin Cardiol; 2011 Jan; 26(1):66-70. PubMed ID: 21045681 [TBL] [Abstract][Full Text] [Related]
8. The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis. Ou H; Huang Z; Mo Z; Xiao J Cardiovasc Toxicol; 2017 Jan; 17(1):1-12. PubMed ID: 27350146 [TBL] [Abstract][Full Text] [Related]
9. Inflammatory disorders and atherosclerosis: new therapeutic approaches. Charakida M; O'Neil F; Masi S; Papageorgiou N; Tousoulis D Curr Pharm Des; 2011 Dec; 17(37):4111-20. PubMed ID: 22204372 [TBL] [Abstract][Full Text] [Related]
10. Seeing the future of bioactive lipid drug targets. Evans JF; Hutchinson JH Nat Chem Biol; 2010 Jul; 6(7):476-9. PubMed ID: 20559310 [No Abstract] [Full Text] [Related]
11. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Bertrand MJ; Tardif JC Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Bäck M Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386 [TBL] [Abstract][Full Text] [Related]
13. Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis. Gieseg SP; Crone EM; Flavall EA; Amit Z Br J Pharmacol; 2008 Feb; 153(4):627-35. PubMed ID: 17700723 [TBL] [Abstract][Full Text] [Related]
14. Does reversal of oxidative stress and inflammation provide vascular protection? Koh KK; Oh PC; Quon MJ Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298 [TBL] [Abstract][Full Text] [Related]
15. Recombinant Human Cytoglobin Prevents Atherosclerosis by Regulating Lipid Metabolism and Oxidative Stress. Ou L; Li X; Chen B; Ge Z; Zhang J; Zhang Y; Cai G; Li Z; Wang P; Dong W J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):162-173. PubMed ID: 28954528 [TBL] [Abstract][Full Text] [Related]
16. Novel anti-inflammatory therapies for the treatment of atherosclerosis. Khan R; Spagnoli V; Tardif JC; L'Allier PL Atherosclerosis; 2015 Jun; 240(2):497-509. PubMed ID: 25917947 [TBL] [Abstract][Full Text] [Related]
17. Polydatin for treating atherosclerotic diseases: A functional and mechanistic overview. Wu M; Li X; Wang S; Yang S; Zhao R; Xing Y; Liu L Biomed Pharmacother; 2020 Aug; 128():110308. PubMed ID: 32480216 [TBL] [Abstract][Full Text] [Related]